Supplementary materials: Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry

Supplementary materials related to the manuscript entitled “Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry”与题为《度普利尤单抗（Dupilumab）对中重度特应性皮炎患者的患者报告结局（patient-reported outcomes）具有持续疗效且安全性良好：来自日常临床实践BioDay登记库的长达5年随访结果》的研究论文相关的补充材料